
Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC
The FDA has granted priority review to a supplemental new drug application (sNDA) for lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) as maintenance therapy in the frontline setting for patients with extensive-stage small cell lung cancer (ES-SCLC) …